Dr Blair is a molecular biologist/ biochemist with 15 years experience in the pharmaceutical industry, recently as a Director of Applied Diagnostics and Surrogates at GlaxoSmithKline, and is a visiting scholar at Cambridge University.

He has been involved in all aspects of early phase drug development from target identification & routine compound screening through to pre-clinical development & Phase II clinical trials. He has developed programmes that support the strategic integration of surrogate biomarkers & diagnostics into the drug development pipe-line from candidate selection to approval & launch. His broad therapeutic area experience includes viral, respiratory, liver and neurodegenerative disease, frequently in collaboration with esteemed academic groups and he was an initial recruit to the GSK Predictive Medicine Group, where he lead pioneering work on integration of testing with influenza, herpes and hepatitis C virus drug development. He is an expert in the field of virology having published more than 30 papers, edited two books and invented 6 patents in the field.

Paul L Wood has completed his Ph.D. from Queen’s University and postdoctoral studies from the NIMH. He is the director of the Metabolomics Unit at Lincoln Memorial University and is professor of pharmacology and physiology. He has published more than 280 peer-reviewed papers, serves as Editor-in-Chief of Metabolomics, and is a member of the editorial board of the JAOA.

Utilization of metabolomics to study mechanisms of pathogenesis in neurogegeneration and oncology

Dr. Shane Rea did his Post Doctoral from McGill University of Colorado.

The goal of the research in the Rea laboratory is to understand the causes of human aging at a molecular genetic level and to use this information to slow the aging process. Dr. Rea’s research group utilizes the nematode Caenorhabditis elegans and focuses specifically on the Mit mutants, which (paradoxically) have disruptions in their mitochondrial electron transport chain yet are long-lived. This model is short-lived (~20 days), self-fertilizing, genetically powerful, easily and cheaply cultivated, and provides excellent molecular and bioinformatic resources. Twenty-five percent of worm genes have human orthologues. Pathways already known to influence aging in C. elegans act similarly in humans (e.g., insulin/IGF-1 like receptor). Mitochondria function similarly in almost all eucaryotes. Life extension in the Mit mutants is restricted to a specific window of mitochondrial dysfunction. The Mit mutants provide a new model for several human mitochondrial-associated diseases. Nuclear DNA damage, cell-cycle checkpoint functions, alternate metabolic pathways, and ROS signalling appear to be central players in lifespan regulation of the Mit mutants. The Rea laboratory also explores the connection between functionally impaired mitochondria, nuclear checkpoint proteins and life extension in the Mit mutants. This research team performs metabolic fingerprinting of the Mit mutants as well as the biochemical and biophysical characterization of the mitochondria from long-lived and short-lived mitochondrial mutants. This group also investigates compensatory biochemical mechanisms that act to offset partial mitochondrial inhibition. They strive to translate their work into higher eucaryotes and to ameliorate human mitochondrial-associated diseases.

Daniel Kassel is an entrepreneur and Founder for SciAnalytical Strategies, Inc. He did his PhD in Chemistry/Bioanalytical from Michigan State University.

Adipocyte Therapeutics

Chris Beecher was a member of the Department of Pathology, University of Michigan School of Medicine until 2011 when he founded NextGen Metabolomics. He was also one of the founders of Metabolon, and Metabolic Analyses. His Ph.D. was granted in 1985 in Pharmaceutical Sciences specializing in Natural Products drug discovery. He has more than 25 years of experience in metabolomics and drug discovery and development, has published over 80 peer-reviewed papers, and is listed as the inventor of 8 patents in metabolomics.

Metabolomics, Chemistry (Natural Products, Analytical, and Physical), Biochemistry, Informatics, Statistics. The development of Metabolomics as the basis of Health Care in the future, and as a research tool in the present

Jeffrey S Patrick has completed his Ph.D. at Purdue University under the guidance of Prof. Graham Cooks. After more than 15 years in biological mass spectrometry and biomarker research, he is currently the Director of Marketed Technology at LECO, a manufacturer of high performance time of flight mass spectrometers. He has published more than 40 papers in reputed journals and presented more than 50 orals at global conferences.

Analytical Chemistry, Chromatography, Proteomics, GC-MS

Dr. D. Marshall Porterfield is now serving as Division Director for Space Life and Physical Sciences in the Human Exploration and Operations Mission Directorate at NASA headquarters in Washington DC. The division includes the Human Research Program, the Physical Sciences Program, and the Space Biology Program, as well as acting as the liaison for the ISS National Lab. The SLPS program includes responsibility for managing all extramural grants and research, as well as the intramural research and engineering assets at six NASA centers. Currently the programmatic focus is on ISS utilization. Dr. Porterfield is on official leave from Purdue University where he is a Professor of Biological Engineering.His teaching and research focus is on advanced physiological sensing technologies for research applications in biology, agriculture, the environment, and medicine. Several of his recent projects involve scanning probe sensor technology, biosensors, bio-MEMS, bio-nanotechnology, and lab-on-a-chip systems. He also is working on understanding how living systems adapt and respond to the spaceflight environment. His work in gravitational and space biology includes cell signaling, biophysical limitations in microgravity, nutrient delivery technology, and biomimetic sensors. He was recognized by the American Society for Gravitational and Space Biology in 2007 with the Halstead Young Investigator Award. Overall his research work at Purdue was recognized by the University Faculty Scholar Award, the University’s top mid career research distinction. His work includes publishing over 100 peer reviewed manuscripts, papers, technical publications, patents, and book chapters; he has also delivered almost 100 invited presentations.His leadership activity includes service as President of the American Society for Gravitational and Space Biology, and he was also recently elected to serve as President for the Institute for Biological Engineering.Dr. Porterfield’s work in the field of biological engineering was recently recognized by election to the College of Fellows for the American Institute for Medical and Biological Engineering, an honor reserved forthe top 2% of medical and biological engineers in US. He was cited for his work \\\\\\\"bridging the interface between engineering and physiology through outstanding contributions to biosensor technology and fundamental cell biology.\\\\\\\"

Advanced physiological sensing technologies for research applications in biology, agriculture, and medicine. Specific projects include: scanning probe sensor technology, biosensors, bioMEMS, bionanotechnology, and lab-on-a-chip systems. He also is working with plant systems in bioregenerative life support systems for spaceflight. His work in this area includes cell signaling, biophysical limitations in microgravity, nutrient delivery technology, and biomimetic sensors.

Ralph Zahn joined BIOCRATES in October 2010 as chief technology officer for the further development of the product pipeline and the affiliated technical and scientific assignments. He holds a PhD in natural science and has a wealth of experience in the field of biotech. After he graduated from biology, he worked as research associate and earned the doctors degree in 1994 at the Max-Planck-Institute for Biochemistry in Munich. At the Cambridge University he obtained a post-graduate doctor degree. He habilitated 2001 at the Institute for Molecular Biology and Biophysics at the Eidgenössischen Technischen Hochschule in Zurich. During his career, he was managing director at BioSafety GmbH and founder and CEO of allprion AG.

NMR structure of the bovine prion protein, NMR structures of three single-residue variants of the human prion protein, metabolomic Buiomarker Research, Molecular Biology and Biophysics

Irwin J Kurland, MD, Ph.D. is an Associate Professor of Medicine, and Director of the Stable Isotope and Metabolomics Core Facility at the Albert Einstein College of Medicine. Dr Kurland\'s laboratory has helped, for over a decade, to establish stable isotope phenotyping methodology for assessing inter-organ fuel switching. Recent papers by the Kurland laboratory illustrate the regulatory role of lysine acetylation on enzymes in tissue specific metabolic networks (Yang et al., J. Proteome Res. 2011), and the linkage between disturbances in fasted/re-fed acetyl CoA levels and dysregulated global lysine acetylation, on the fasted/re-fed metabolic network response (Vaitheesvaran et al., PLOS One 2012).

Diabetes, Metabolomics Syndrome,GC/MS flux profiling,Gas chromatography/Mass spectrometry (GC/MS).

Dr. SivanesanDakshanamurthyis an Associate Professor in the Departments of Oncology and Experimental & Clinical Therapeutics, Georgetown University Medical Center. My area of expertise is multi-disciplinary in nature such as drug design (in-silico/in-vitro), chemo-and clinical-informatics, metabolomics, molecular biology and medicinal chemistry. I have published more than 53 peer reviewed journal articles and have 10 patents issued/applied.

High-throughput chemo-informatics, drug-repurposing, drug-protein docking, and molecular dynamics simulations

Dr. Karp has been a bioinformatics researcher for over 10 years in the areas of bioinformatics databases, metabolic-pathway bioinformatics, and database interoperation. He has authored numerous publications on these topics, and is the developer of the EcoCyc database, and the Pathway Tools software. EcoCyc is a database describing the genome and biochemical machinery of the bacterium E. coli. The Pathway Tools is a software environment for constructing, querying, and WWW publishing of pathway/genome databases such as EcoCyc. Dr. Karp\'s bioinformatics research has been funded by the NIH National Center for Research Resources and National Library of Medicine.

Bioinformatics databases, Metabolic-pathway Bioinformatics, and database Interpretation.

Danilo Tagle, Ph.D., is Program Director for Neurogenetics at the National Institute of Neurological Disorders and Stroke (NINDS), where he is involved in developing programs in genomics and proteomics for basic and translational research in inherited brain disorders. Dr. Tagle obtained his Ph.D. in molecular biology and genetics from Wayne State University in 1990. He was a National Institutes of Health (NIH) National Research Service Award (NRSA) postdoctoral fellow in human genetics in the laboratory of Dr. Francis S. Collins at the University of Michigan. Prior to joining NINDS in 2001, Dr. Tagle was an investigator and Section Head of Molecular Neurogenetics at the National Human Genome Research Institute (NHGRI) since 1993 and was involved in the positional cloning of genes for Huntington disease, ataxia-telangiectasia, and Niemann-Pick type C disease.

Dr. Tagle was an intramural investigator and Section Head of Molecular Neurogenetics at the National Human Genome Research Institute (NHGRI) since 1993 and was involved in the positional cloning of genes for Huntington disease, ataxia-telangiectasia, and Niemann-Pick type C disease.

Preeti Bais holds a BS in computer Science from National Institute of Technology (Bhopal, India), MS in Bioinformatics from Brandeis University (Waltham, MA) and a PhD in Bioinformatics and Computational Biology with a minor in Statistics from Iowa State University (Ames, Iowa). For her PhD work, she combined data from 11 different GCMS and LCMS based platforms on 70 single gene knock out mutants of Arabidopsis to create the plantmetabolomics.org database and metabolomics data analysis pipeline. As a principal scientist at Stemina Biomarker Discovery (Madison, WI), she used metabolomics and stem cell technology for drug toxicity screening studies, NCI funded metabolomics analysis of mouse in-vivo assays to understand drug efficacy in human GBM (Glioblastoma multiforme), and metabolomics analysis of patient blood samples to detect autism. She has recently joined the computational sciences and statistical analysis group at the Jackson lab’s new research institute - JAX Genomics Medicine (JGM) at University of Connecticut (Farmington, CT). This independent, nonprofit organization focuses on mammalian genetics research to advance human health and has been working in various disease areas like cancer, neurodegenerative disorders to name a few.

Developing metabolomics as a systems biology tool, statistical analysis, pattern recognition, metabolic network analysis, plant metabolomics, data analysis pipeline development, metabolomics standards